Depression

Pediatric Antidepressant Prescription Rates Increased 66%

February 27, 2024 - A recent study published in Pediatrics, the journal of the American Academy of Pediatrics (AAP), revealed a significant increase in antidepressant prescriptions among adolescents, teens, and young adults between January 2016 and December 2022, indicating a decline in mental health following the COVID-19 pandemic. Researchers assessed data from the...

Read More


More Articles

FDA Investigates the Safety of GLP-1 Weight Loss Drugs

by Veronica Salib

Yesterday, on January 11, 2024, the United States FDA issued a drug safety communication updating the public on an ongoing investigation of glucagon-like peptide-1 receptor agonists. The administration...

Understanding Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)

by Veronica Salib

Although most people think of selective serotonin reuptake inhibitors (SSRIs) when discussing antidepressants, serotonin and norepinephrine reuptake inhibitors (SNRIs) also play a critical role in managing major depressive disorder and...

Psilocybin-Assisted Group Therapy Manages MDD in Cancer Patients

by Veronica Salib

On December 18, 2023, researchers published a study in Cancer, a journal of the American Cancer Society, evaluating the safety, feasibility, and efficacy of psilocybin-assisted group therapy to manage...

Sage Therapeutics Announces Wholesale Cost of Zuranolone, $15,900

by Veronica Salib

On November 7, 2023, Sage Therapeutics, the manufacturer of ZURZUVAE (zuranolone), announced that the wholesale acquisition cost of the postpartum depression drug would be $15,900 for a 14-day...

Psychiatrists Prescribe or Recommend Ozempic, Other Weight Loss Drugs

by Veronica Salib

On November 3, 2023, the New York Times broke a story analyzing the role of Ozempic and other weight loss drugs in mental health or psychiatric care. Upon reaching out to 13 psychiatric departments at...

Managing Pediatric Behavioral Health with Pharmacological Treatments

by Veronica Salib

Pediatric mental and behavioral health is a large field of research that can be challenging to tackle. Although these conditions are already difficult to manage in adults, pediatric care requires even more consideration when approaching...

FDA Approves Zuranolone for Postpartum Depression

by Veronica Salib

Last week, the United States Food and Drug Administration approved the first oral treatment for postpartum depression (PPD). Zuranolone was approved on August 4, 2023, just days after a study in the...

Zuranolone Effectively and Safely Treats Postpartum Depression

by Veronica Salib

A study published in the American Journal of Psychiatry on July 26, 2023, proved that zuranolone could effectively and safely treat postpartum depression. The study supports the priority review granted...

Applications of Psilocybin in Mental Health Disorder Treatments

by Veronica Salib

Over the past few years, researchers have explored psychedelics, including lysergic acid diethylamide (LSD), ketamine, 3,4-methyl​enedioxy​methamphetamine (MDMA), and more for treating mental health disorders. Among the many...

Top 3 Use Cases for Psychedelics, Understanding Ongoing Research

by Veronica Salib

Throughout the past decade, psychedelics have become a primary area of interest for ongoing clinical research. Scientists have hypothesized multiple clinical use cases for these medications despite primarily being scheduled or illicit...

Ketamine and ECT Equally Effective for Treatment-Resistant Depression

by Veronica Salib

An open-label, randomized, noninferiority trial published in the New England Journal of Medicine revealed that ketamine and electroconvulsive therapy (ECT) were equally effective at managing...

Oral Ketamine Treatment: An Alternative to Ketamine Infusions

by Veronica Salib

Data from the WHO estimates that 230 million people globally have depression. Although many traditional treatments exist for depression, roughly 33% of people do not respond to medications. As a result, researchers have searched for...

FDA Approves New Adjunctive Treatment for Depression

by Veronica Salib

Major depressive disorder (MDD) — commonly referred to as depression — affects approximately 20% of adults in the United States. MDD symptoms may include depressed mood, appetite changes,...

A Single Dose of Psilocybin Can Reduce MADRS Score

by Veronica Salib

BMC Psychiatry states that up to one-third of patients with major depressive disorder become resistant to treatment, otherwise known as treatment-resistant depression. In recent years, psilocybin and...

Exploring Psychedelics to Treat Mental Health Issues

by Veronica Salib

In recent years, psychedelics have been explored for pain management and treatment-resistant depression. While receiving criticism from the general public, clinicians and researchers are working tirelessly to prove the safety and efficacy...

How Brain-in-a-Dish Technology Can Impact the Treatment of MDD

by Veronica Salib

According to the WHO, major depressive disorder (MDD) is the most common illness, affecting approximately 280 million people worldwide. That said, treating depression presents a unique challenge for providers. With several medications...

FDA Approved AUVELITY for Major Depressive Disorder in Adults

by Veronica Salib

On August 19, 2022, the FDA approved AUVELITY — an oral medication manufactured by Axsome Therapeutics — for the treatment of major depressive disorder (MDD) in adults. This medication...

Depression, Anxiety Prescriptions Soar During Coronavirus Pandemic

by Hayden Schmidt

In the year prior to the start of the coronavirus pandemic, 15.8% of American adults were using prescription medication to support their mental health; two years later, that number has risen to 23%,...

Psychotropic Medications Linked to an Increased Risk of Parkinson’s

by Veronica Salib

A study published in the Annals of Clinical and Translational Neurology found that psychotropic medication use in women may be associated with an increased risk of developing Parkinson’s disease...

Recent Articles